Tenosynovial Tumor Pathology and Treatment

Tenosynovial tumours encompass a spectrum of benign neoplasms arising from the synovial lining of joints, bursae and tendon sheaths. Although histologically non-malignant, tenosynovial giant cell tumours (TGCT) can exhibit locally aggressive behaviour, particularly in the diffuse subtype, leading to pain, joint dysfunction and high rates of recurrence. Pathogenesis revolves around aberrant activation of the colony-stimulating factor 1 (CSF-1) pathway, which recruits macrophages and drives synovial proliferation. Traditional management has centred on synovectomy—either arthroscopic or open—with occasional use of adjuvant radiotherapy to reduce local relapse. Recent advances in molecular profiling have identified CSF-1 receptor inhibitors as systemic options for patients with unresectable or relapsing disease. A multidisciplinary approach, integrating high-resolution imaging, surgical precision and targeted pharmacotherapy, now underpins long-term control and preservation of joint function.

Research from Nature Portfolio

A landmark multi-institutional study has confirmed the durable activity of a CSF-1 receptor–blocking agent in advanced TGCT. In this retrospective cohort, a substantial proportion of patients achieved complete or partial tumour regression, with progression-free survival rates of just under three-quarters at one year and approximately half at five years. Treatment was generally well tolerated, with most adverse events being mild to moderate and largely reversible. Notably, symptom relief and functional improvement often persisted after treatment cessation, highlighting the value of targeted systemic therapy for diffuse disease unsuitable for repeat surgery.

Tenosynovial Tumor Pathology and Treatment publication trend

The graph below shows the total number of articles in tenosynovial tumor pathology and treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Synovium: The connective tissue lining the inner surface of joints, bursae and tendon sheaths.

Tenosynovial giant cell tumour (TGCT): A benign proliferative lesion of the synovium characterised by mononuclear cells and multinucleated giant cells.

Diffuse-type TGCT: A form with widespread synovial involvement, poorly defined margins and higher propensity for recurrence.

Localised-type TGCT: A well-circumscribed lesion often amenable to complete surgical excision.

Colony-stimulating factor 1 receptor (CSF-1R): A tyrosine kinase receptor that mediates macrophage recruitment and proliferation in TGCT, representing a target for systemic therapy.

Synovectomy: Surgical removal of diseased synovial tissue to debulk or eradicate tenosynovial tumours.

Recurrence rate: The proportion of treated cases in which tumour regrowth is observed during follow-up.

References

1. MRI of diffuse-type tenosynovial giant cell tumour in the knee: a guide for diagnosis and treatment response assessment. Insights into Imaging (2023).
2. Treatment, recurrence rates and follow-up of Tenosynovial Giant Cell Tumor (TGCT) of the foot and ankle—A systematic review and meta-analysis. PLOS ONE (2021).
3. Low-dose external beam radiotherapy as a postoperative treatment for patients with diffuse pigmented villonodular synovitis of the knee. Acta Orthopaedica (2012).
4. Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory Disease. JAAOS Global Research and Reviews (2020).